Syndax Pharmaceuticals In... (SNDX)
Syndax Pharmaceuticals Statistics
Share Statistics
Syndax Pharmaceuticals has 85.36M shares outstanding. The number of shares has increased by 0.46% in one year.
| Shares Outstanding | 85.36M |
| Shares Change (YoY) | 0.46% |
| Shares Change (QoQ) | 0.31% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 83.5M |
| Failed to Deliver (FTD) Shares | 18 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 22.38M, so 26.22% of the outstanding shares have been sold short.
| Short Interest | 22.38M |
| Short % of Shares Out | 26.22% |
| Short % of Float | 27.6% |
| Short Ratio (days to cover) | 8.36 |
Valuation Ratios
The PE ratio is -7.25 and the forward PE ratio is -3.8. Syndax Pharmaceuticals's PEG ratio is -0.28.
| PE Ratio | -7.25 |
| Forward PE | -3.8 |
| PS Ratio | 0 |
| Forward PS | 2.6 |
| PB Ratio | 2.74 |
| P/FCF Ratio | -9.45 |
| PEG Ratio | -0.28 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Syndax Pharmaceuticals Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10, with a Debt / Equity ratio of 0.
| Current Ratio | 10 |
| Quick Ratio | 10 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0.29 |
| Cash Flow / Debt | -98.23 |
| Interest Coverage | -1105.55 |
Financial Efficiency
Return on equity (ROE) is -0.38% and return on capital (ROIC) is -41.37%.
| Return on Equity (ROE) | -0.38% |
| Return on Assets (ROA) | -0.34% |
| Return on Capital (ROIC) | -41.37% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.14M |
| Employee Count | 184 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -33.83% in the last 52 weeks. The beta is 0.9, so Syndax Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.9 |
| 52-Week Price Change | -33.83% |
| 50-Day Moving Average | 14.16 |
| 200-Day Moving Average | 18.21 |
| Relative Strength Index (RSI) | 56.88 |
| Average Volume (20 Days) | 2.39M |
Income Statement
| Revenue | n/a |
| Gross Profit | -12K |
| Operating Income | -229.95M |
| Net Income | -209.36M |
| EBITDA | -229.94M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -2.98 |
Balance Sheet
The company has 295.39M in cash and 1.64M in debt, giving a net cash position of 293.76M.
| Cash & Cash Equivalents | 295.39M |
| Total Debt | 1.64M |
| Net Cash | 293.76M |
| Retained Earnings | -902.4M |
| Total Assets | 425.81M |
| Working Capital | 355.43M |
Cash Flow
In the last 12 months, operating cash flow was -160.6M and capital expenditures 0, giving a free cash flow of -160.6M.
| Operating Cash Flow | -160.6M |
| Capital Expenditures | 0 |
| Free Cash Flow | -160.6M |
| FCF Per Share | -2.29 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SNDX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -18.99% |
| FCF Yield | -12% |
Analyst Forecast
The average price target for SNDX is $37, which is 135.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $37 |
| Price Target Difference | 135.8% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
Scores
| Altman Z-Score | 8.46 |
| Piotroski F-Score | 3 |